GETLIN LAWRENCE W 4
4 · ProUroCare Medical Inc. · Filed Jan 2, 2013
Insider Transaction Report
Form 4
GETLIN LAWRENCE W
Director
Transactions
- Exercise/Conversion
Convertible Note
2012-12-28$1.00/sh−5,243$5,243Exercise: $1.10Exp: 2012-12-28→ Common stock, $0.00001 par value (5,243 underlying) - Exercise/Conversion
Common Stock, $0.00001 par value
2012-12-28$1.10/sh+5,243$5,767→ 65,015 total - Award
Common stock, $0.00001 par value
2012-12-28$0.64/sh+8,594$5,500→ 59,772 total - Award
Common Stock, $0.00001 par value
2013-01-02$0.64/sh+20,000$12,800→ 85,015 total
Holdings
Convertible notes
Exercise: $1.30Exp: 2013-09-15→ Common Stock, $0.00001 par value (19,231 underlying)- 2,265
Stock Options
Exercise: $0.92Exp: 2018-06-27→ Common Stock, $0.00001 par value (2,265 underlying) - 28,736
Stock Options
Exercise: $0.87Exp: 2018-08-09→ Common stock, $0.00001 par value (28,736 underlying) - 25,000
Stock Options
Exercise: $0.60Exp: 2019-08-09→ Common stock, $0.00001 par value (25,000 underlying)
Footnotes (5)
- [F1]Currently exercisable.
- [F2]Annual option award pursuant to the Issuer's compensation policy for Directors upon their re-election to the Board of Directors. The seven-year options vest ratably over 12 months.
- [F3]On December 28, 2012, the reporting person converted a convertible promissory note in the principal amount of $5,200, along with accrued interest thereon of $568, into common shares pursuant to the terms of the note. The transaction was approved by the Company's Board of Directors and is exempt under section 16b-3(d).
- [F4]Shares issued to directors in payment of directors' fees earned during the period from July 1, 2012 and December 31, 2012, in lieu of cash. The Issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rule 16b-3(d).
- [F5]On January 2, 2013, the issuer issued 20,000 shares to the reporting person in lieu of cash for $12,800 of consulting fees due to the reporting person. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).